INTEGRA LIFESCIENCES HOLDINGS CORP·4

Mar 12, 5:16 PM ET

Knight Lea Daniels 4

Research Summary

AI-generated summary

Updated

Integra Lifesciences (IART) CFO Knight Lea Daniels Receives RSU Award

What Happened

  • Knight Lea Daniels, Chief Financial Officer of Integra LifeSciences (IART), was granted 111,179 restricted stock units (RSUs) on March 11, 2026 (derivative acquisition, code A).
  • To cover tax withholding related to the grant, 8,089 shares were surrendered/withheld at an effective price of $9.61 per share, generating $77,735 (transaction code F). This withholding is a disposition to satisfy tax obligations, not an open-market sale.

Key Details

  • Transaction dates: March 11, 2026 (grant and withholding); filing date: March 12, 2026 (timely).
  • Grant: 111,179 RSUs, acquisition price $0.00 (standard for RSU awards).
  • Withholding: 8,089 shares @ $9.61 = $77,735 (tax withholding/disposition).
  • Shares owned after transaction: not specified in the filing.
  • Footnote: The RSU award vests 33% on the first and second anniversaries and 34% on the third anniversary of the grant date (3/11/2026).
  • Transaction codes: A = award/grant; F = payment of exercise price or tax liability (here used for share withholding).

Context

  • RSUs are compensation that convert to shares only as they vest; the grant itself is routine executive compensation and does not represent an open-market purchase.
  • The 8,089-share disposition was a tax-withholding action tied to the RSU grant, not a market sale intended to realize investment gains.
  • For retail investors, grants signal future potential share issuance as they vest; withholding to cover taxes is common and generally not an indicator of sentiment.